195
Participants
Start Date
September 30, 2007
Primary Completion Date
October 31, 2008
Study Completion Date
November 30, 2008
1-Methylnicotinamide (1-MNA)
Following a 6-8-week placebo and dietary-controlled baseline period, 195 men and women will be randomized to receive placebo, 30 mg MNA or 90 mg MNA three times daily for twelve weeks.
Placebo
Placebo
Institut de Cardiologie de Montreal, Montreal
Commonwealth Medical Clinic
UNKNOWN
Institut de Recherches Cliniques de Montreal
OTHER
Clinique des maladies lipidiques de Québec
UNKNOWN
Centre de médecine genique communautaire
UNKNOWN
Omnispec clinical research Inc
UNKNOWN
Manna Research
UNKNOWN
St. Jerome Medical Research Inc.
OTHER
Royal Victoria Hospital, Canada
OTHER
Hotel Dieu Hospital
OTHER
St Michael's Hospital Health Center
UNKNOWN
Cambridge Cardiac Care Centre
OTHER
Maritime Research Center
OTHER
Rhodin Recherche Clinique
UNKNOWN
Queen Elizabeth II Health Sciences Centre
OTHER
First Line Medical Ltd
UNKNOWN
Diabetes Research, Vancouver General Hosp
UNKNOWN
The Allin Clinic
OTHER
St Paul's Hospital Healthy Heart Clinical Trial
UNKNOWN
The Clinical Trials Centre
UNKNOWN
Recherche Invascor Inc
OTHER
MSHJ Research Associates
OTHER
Dr.Kim W Tan
UNKNOWN
Montreal Heart Institute
OTHER